This Partner Update is intended for healthcare providers assessing patients for COVID-19 infection or asymptomatic screening.
The purpose of this Partner Update is to address the emergence of SARS-CoV-2 Omicron variant of concern (VOC) and its potential impact to COVID-19 diagnostic molecular tests offered by Dynacare.
Currently there is no evidence to suggest that SARS-CoV-2 test performance is impacted by Omicron or any other circulating VOCs.
Read More -
Testing Update: SARS-CoV-2 Variant of Concern Screening and Impact on COVID-19 Diagnostic Molecular Testing Performance